Sanofi buys US biopharma group Blueprint in $9.1 billion deal

Sanofi buys US biopharma group Blueprint in $9.1 billion deal

French pharmaceutical giant Sanofi has agreed to acquire US-based biopharmaceutical company Blueprint Medicines Corporation in a deal valued at approximately $9.1 billion. The acquisition, announced on June 2, 2025, aims to expand Sanofi's portfolio in rare immunological diseases and add to its early-stage pipeline in immunology.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. This acquisition includes Blueprint's approved medicine Ayvakit/Ayvakyt (avapritinib) for systemic mastocytosis, a rare immunological disease, and a promising pipeline of early-stage immunology drugs, including elenestinib and BLU-808.

Sanofi's CEO, Paul Hudson, stated, "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company." Kate Haviland, CEO of Blueprint Medicines, expressed pride in the company's achievements and looked forward to collaborating with Sanofi to bring life-changing medicines to more patients.

Systemic mastocytosis is a rare immunologic disorder characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The symptoms can include anaphylaxis, bone disease, gastrointestinal distress, and skin lesions. Ayvakit achieved net revenues of $479 million in 2024 and nearly $150 million in Q1 2025, representing year-on-year growth of over 60 percent.

The acquisition is expected to be completed in the third quarter of 2025 and will not have a significant impact on Sanofi's financial guidance for 2025. It is immediately accretive to gross margin and business operating income and EPS after 2026. Sanofi plans to finance the transaction with a combination of cash on hand and new debt.

References:
[1] https://www.marketscreener.com/quote/stock/BLUEPRINT-MEDICINES-CORPO-22033569/news/Sanofi-buys-US-biopharma-group-Blueprint-in-9-1-billion-deal-50126155/
[2] https://www.globenewswire.com/news-release/2025/06/02/3091539/0/en/Press-Release-Sanofi-to-acquire-Blueprint-Medicines-expanding-portfolio-in-rare-immunological-disease-and-adding-early-stage-pipeline-in-immunology.html